Bacteriophages

1. Adsorption: Phage Acquisition of Bacteria

   • John J. Dennehy, Stephen T. Abedon

2. Bacteria-Phage Antagonistic Coevolution and the Implications for Phage Therapy

   • Michael A. Brockhurst, Britt Koskella, Quan-Guo Zhang

3. Bacteriophage as Biocontrol Agents

   • David R. Harper

4. Bacteriophage Discovery and Genomics

   • Graham F. Hatfull

5. Bacteriophage Ecology

   • John J. Dennehy, Stephen T. Abedon

6. Bacteriophage Manufacturing: From Early Twentieth-Century Processes to Current GMP

   • Krzysztof Regulski, Patrick Champion-Arnaud, Jérôme Gabard

7. Bacteriophage Pharmacology and Immunology

   • Krystyna Dąbrowska, Andrzej Górski, Stephen T. Abedon

8. Bacteriophage Use in Molecular Biology and Biotechnology

   • Nathan Brown, Chris Cox

9. Bacteriophage Utilization in Animal Hygiene

   • Sarah Klopatek, Todd R. Callaway, Tryon Wickersham, T. G. Sheridan, D. J. Nisbet

10. Bacteriophage-Mediated Horizontal Gene Transfer: Transduction

    • Christine L. Schneider

11. Bacteriophages as Bio-sanitizers in Food Production and Healthcare Settings

    • Sudhakar Bhandare, Lawrence Goodridge

12. Bacteriophages in Nanotechnology: History and Future

    • Paul Hyman, Jenna Denyes

13. Biofilm Applications of Bacteriophages

    • Catarina Milho, Maria Daniela Silva, Sanna Sillankorva, D. R. Harper

14. Clinical Trials of Bacteriophage Therapeutics

    • Shawna McCallin, Harald Brüssow

15. Crop Use of Bacteriophages

    • Jeffrey B. Jones, Antonet M. Svircev, Aleksa Ž. Obradović

16. Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia

    • Ryszard Międzybrodzki, Naomi Hoyle, Fikria Zhvaniya, Marzanna Łusiak-Szelachowska, Beata Weber-Dąbrowska, Małgorzata Łobocka et al.

17. Detection of Bacteriophages: Electron Microscopy and Visualisation

    • David M. Belnap

18. Detection of Bacteriophages: Phage Plaques

    • Stephen T. Abedon

19. Detection of Bacteriophages: Sequence-Based Systems

    • Siân V. Owen, Blanca M. Perez-Sepulveda, Evelien M. Adriaenssens

20. Detection of Bacteriophages: Statistical Aspects of Plaque Assay

    • Stephen T. Abedon, Tena I. Katsaounis

The intention is to provide a defininitive reference work on the technological and therapeutic applications of bacteriophages. The main areas to be covered are indicated in the subtitles. It is intended to avoid an overdependence on reciting the history of the approach and rather to concentrate on its practical utility, albeit placing that in its appropriate context.

• Bacteriophages
• Host resistance
• Phage infection
• Biocontrol agents
• Environmental Hygiene
• antibiotic resistance

• Evolution Biotechnologies, Milton Keynes, United Kingdom

  David R. Harper, Malcolm L. McConville

• Dept. of Microbiology, The Ohio State University Dept. of Microbiology, Mansfield, USA

  Stephen T. Abedon

• GeneWEAVE Biosciences, Roche Molecular Systems GeneWEAVE Biosciences, Los Gatos, USA

  Benjamin H. Burrowes

Dr. David Harper has a scientific background in virology and microbiology is the Chief Officer of Evolution Biotechnologies. He was the founder, CEO and CSO of Biocontrol Limited and CSO of AmpliPhi Biosciences and managed the first modern regulated clinical trial to demonstrate the efficacy of bacteriophages. He is a member of the Alternatives to Antibiotics panel, a collaboration between the Wellcome Trust and the UK Department of Health.

Dr. Stephen Abedon has been a member of the faculty of the Ohio State University, Department of Microbiology, for over 20 years. He has been studying bacteriophages for 30-plus years and has approximately 100 phage-based publications including six monographs or equivalents on phages which he has edited (five) or authored (one), along with three more edited volumes currently in progress. Additional information and resources can be found at abedon.phage.org.

Dr Ben Burrowes gained his PhD in Medical Microbiology from Texas Tech University Health Sciences Center in 2010, where his research focus was the development of therapeutic bacteriophages with extended host range using in vitro evolution. Upon leaving Texas, Dr Burrowes worked at Biocontrol Inc. (now AmpliPhi Biosciences Corporation) developing multiple human phage therapy preparations targeting several major bacterial pathogens. Since 2013 Dr Burrowes has worked for GeneWEAVE Biosciences (now a division of Roche Molecular Systems) assisting in the development of rapid diagnostics for drug resistant bacteria using a proprietary phage-based platform.

Policies and ethics